Paul M. Epstein, PhDAssociate Professor, Department of Cell Biology
|
Degree | Institution | Major |
---|---|---|
BA | COLUMBIA UNIVERSITY | Chemistry |
PhD | ALBERT EINSTEIN COLLEGE OF MEDICINE | Molecular Biology |
Awards
Name of Award/Honor | Awarding Organization |
---|---|
Principal inventor on US Patent Application No. 20090105281 on “Methods of Treating Inflammation” | United States Patent and Trademark Office |
Principal inventor on US Patent No. 5,885,834 on “Synthesis of Antisense Oligodeoxynucleotide of Phosphodiesterase and Inducement of Apoptosis in Human Lymphoblastoid Cells | United States Patent and Trademark Office |
Fellow of the Rosalie B. Hite Foundation for Cancer Research | Rosalie B. Hite Foundation |
NIH Predoctoral Trainee | NIH |
Scholarship for Woods Hole Marine Biological Laboratory Physiology Program | Marine Biological Laboratory |
Dean’s List Columbia College | Columbia College |
New York State Regents Scholarship | New York State |
Name & Description | Category | Role | Type | Scope | Start Year | End Year |
---|---|---|---|---|---|---|
Committee on Undergraduate Medical Education (CUME) | Education Committee | Chair | UConn Health | University | 2023 | 2028 |
Cells | Professional/Scientific Journal | Editorial Board | External | International | 2020 | |
UCH Medical School Coaching Program | Advisory Committee | Advisor | UConn Health | University | 2016 | 2020 |
American Association for Cancer Research | Professional/Scientific Organization | Member | External | National | 2007 | |
Biochemical Journal | Editorial Board | Editorial Advisor | External | International | 2003 | |
Medical and Dental Student Research Day Committee | Research Committee | Member and Chair | UConn Health | University | 1996 | 2012 |
Committee on Student Research | Research Committee | Chair | UConn Health | University | 1994 | 2012 |
NIH Physiological Chemistry Study Section | Study Section | Member | External | National | 1989 | |
Director of the Graduate Program in Cell and Molecular Pharmacology | Education Committee | Director | UConn Health | University | 1988 | 1999 |
Society for Neuroscience | Professional/Scientific Organization | Member | External | National | 1983 | |
American Society for Pharmacology and Experimental Therapeutics | Professional/Scientific Organization | Member | External | International | 1975 | |
New York Academy of Sciences | Professional/Scientific Organization | Member | External | International | 1975 | |
American Association for the Advancement of Science | Professional/Scientific Organization | Member | External | International | 1975 | |
Sigma XI | Professional/Scientific Organization | Member | External | International | 1975 |
Dr. Epstein's laboratory has been studying cyclic nucleotide phosphodiesterases (PDE), a large family of isozymic enzymes which control the cellular levels of two key signal transduction molecules, cAMP and cGMP, and thereby play a role in controlling a wide variety of critical cellular functions. Through cloning and sequence analysis, he is identifying different forms of phosphodiesterase and determining their expression and subcellular localization during normal development and in association with pathophysiological disease states. One disease sate he is concentrating on in particular is leukemia. He has found that a 63 kDa form of calmodulin-dependent PDE (PDE1B1) is expressed in leukemia cells but not in normal quiescent human lymphocytes. He cloned the cDNA for this gene and developed antisense oligonucleotides (ASODNs) against it. When he disrupts the expression of the gene for PDE1B1 with these AS ODNs, it triggers apoptosis in leukemic cells without any effect on normal resting lymphocytes. Hence these studies pioneer the basis for a possible new therapy for leukemia. Similar studies are now being undertaken with respect to breast cancer.
Not accepting lab rotation students at this time
Lab Rotation Projects
Most of the emphasis of the lab at the moment is identifying forms of PDE as targets for inducing apoptosis of cancer cells. We are also collaborating with two colleagues in Pharmacology, Drs. Joel Pachter and Stefan Brocke, to examine a potential role for inhibitors of PDE to strengthen the blood brain barrier as a means of treating Alzheimer’s Disease, and to examine a potential role for PDEs in regulating lymphocyte chemotaxis and transendothelial migration in relation to treating multiple sclerosis. Students are free to design their own projects, but possibilities are:
Project 1: We have found that stimulating the cAMP signaling pathway can overcome the resistance to inducing apoptosis in leukemic cells from patients that have developed glucocorticoid resistance (see: Tiwari, S. et al. “Type 4 cAMP Phosphodiesterase (PDE4) Inhibitors Augment Glucocorticoid-Mediated Apoptosis in B Cell Chronic Lymphocytic Leukemia (B-CLL) in the Absence of Exogenous Adenylyl Cyclase Stimulation.” Biochem. Pharmacol. 69:473-483, 2005). The mechanism of this effect is, however, still unknown. One hypothesis we have is that cAMP signaling may enhance the expression and/or function of the BH3-only proapoptotic proteins BAD and BIM, leading to apoptosis of these resistant cells, and this could be examined as a rotation project.
Project 2: Work from Dr. Pachter’s laboratory has pioneered a method for culturing primary brain microvascular endothelial cells (BMEC) in a manner in which the tight junctions of the endothelial cells are preserved (see: Song, L. and Pachter, J. S. Culture of murine brain microvascular endothelial cells that maintain expression and cytoskeletal association of tight junction-associated proteins. In Vitro Cell Dev Biol Anim, 39: 313-320, 2003). This therefore provides a model in vitro system in which to examine the effects of agents on the blood brain barrier. We hypothesize that PDE inhibitors will strengthen the blood brain barrier by enhancing the expression of expression of the tight junction-associated proteins, claudin-5, occludin, and zona occludin-1 (ZO-1), and this could be examined as a rotation project.
Project 3: PDE4 inhibitors have been shown to be effective in ameliorating the pathogenesis associated with multiple sclerosis (MS) in EAE animal models of this disease, though it is unclear how they work in this regard. We hypothesize that PDE4 inhibitors block T lymphocyte chemotaxis and transendothelial migration through their ability to induce phosphorylation and inactivation of rhoA resulting in decreased phosphorylation of myosin light chain, and, with the help of Dr. Brocke who is a renowned expert in this area, this can be tested in a rotation project.
Journal Articles
-
Editorial: Cyclic Nucleotide Phosphodiesterases (PDEs) in Immune Regulation and Inflammation.
Frontiers in pharmacology 2022 Jun;13950480
-
Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
Cells 2022 Feb;11,(4):
-
PDE8 controls CD4(+) T cell motility through the PDE8A-Raf-1 kinase signaling complex.
Cellular signalling 2017 Aug;4062-72
-
Different phosphodiesterases (PDEs) regulate distinct phosphoproteomes during cAMP signaling.
Proceedings of the National Academy of Sciences of the United States of America 2017 Jul;114(30):7741-7743
-
Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation.
Frontiers in pharmacology 2016 Jan;7259
-
Inhibition of breast cancer cell migration by activation of cAMP signaling.
Breast cancer research and treatment 2015 May;152(1):17-28
-
Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells.
Frontiers in pharmacology 2015 Jan;6230
-
Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells.
SpringerPlus 2013 Dec;2680
-
Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac.
The Biochemical journal 2013 Dec;456(3):463-73
-
Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells.
Biochemical pharmacology 2010 Feb;79(3):321-9
-
PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.
PloS one 2010 Jan;5(8):e12011
-
Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes.
Biochemical and biophysical research communications 2006 Jun;345(2):713-9
-
Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Biochemical pharmacology 2005 Feb;69(3):473-83
-
Zaprinast stimulates extracellular adenosine accumulation in rat pontine slices.
Neuroscience letters 2004 Nov;371(1):12-7
-
Elevation of intracellular cAMP evokes activity-dependent release of adenosine in cultured rat forebrain neurons.
The European journal of neuroscience 2004 May;19(10):2669-81
-
Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001 Nov;21(22):9068-76
-
Structure and promoter activity of the mouse CDC25A gene.
Mammalian genome : official journal of the International Mammalian Genome Society 2000 Dec;11(12):1063-9
-
Antisense inhibition of phosphodiesterase expression.
Methods (San Diego, Calif.) 1998 Jan;14(1):21-33
-
Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes.
Cell biochemistry and biophysics 1998 Jan;28(2-3):135-60
-
Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells.
Proceedings of the National Academy of Sciences of the United States of America 1996 Oct;93(20):11236-41
-
A novel cyclic GMP stimulated phosphodiesterase from rat brain.
Biochemical and biophysical research communications 1994 Dec;205(3):1850-8
-
Phosphotyrosine phosphatase activity in human platelets.
Life sciences 1991 Jan;49(1):29-37
-
Relationship between phosphorylation and cytochrome P450 destruction.
Archives of biochemistry and biophysics 1990 Dec;283(2):285-92
-
Calmodulin dependence of transferrin receptor recycling in rat reticulocytes.
The Biochemical journal 1990 Feb;266(1):261-72
-
Echothiophate and cogeners decrease the voltage dependence of end-plate current decay in frog skeletal muscle.
The Journal of pharmacology and experimental therapeutics 1989 Dec;251(3):810-6
-
Phosphorylation of cytochrome P450: regulation by cytochrome b5.
Archives of biochemistry and biophysics 1989 Jun;271(2):424-32
-
Inverse relationship between cytochrome P-450 phosphorylation and complexation with cytochrome b5.
Archives of biochemistry and biophysics 1987 Dec;259(2):441-8
-
Identification and characterization of a Ca2+-calmodulin-sensitive cyclic nucleotide phosphodiesterase in a human lymphoblastoid cell line.
The Biochemical journal 1987 Apr;243(2):533-9
-
Ontogenetic changes in adenylate cyclase, cyclic AMP phosphodiesterase and calmodulin in chick ventricular myocardium.
The Biochemical journal 1987 Apr;243(2):525-31
-
Photoaffinity labelling of a 33-35,000 dalton protein in cardiac, skeletal and smooth muscle membranes using a new 125I-labelled 1,4-dihydropyridine calcium channel antagonist.
Life sciences 1986 Dec;39(25):2401-9
-
Muscarinic receptors in rat superior cervical ganglia
Annals of the New York Academy of Sciences 1986 Jan;VOL. 46394-95
-
Displacement of [3H]phencyclidine binding to Torpedo electric organ membrane by calcium channel antagonists.
Biochemical pharmacology 1984 Dec;33(24):4087-9
-
The Effect of Dexamethasone on Parathyroid Hormone Stimulation of Adenylate Cyclase in ROS 17/2.8 Cells.
Endocrinology 1984 Jan;
-
Catalytic and kinetic properties of purified high-affinity cyclic AMP phosphodiesterase from dog kidney.
Archives of biochemistry and biophysics 1982 Oct;218(1):119-33
-
Interaction of calcium antagonists with cyclic AMP phosphodiesterases and calmodulin.
Biochemical and biophysical research communications 1982 Apr;105(3):1142-9
-
Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin.
Proceedings of the National Academy of Sciences of the United States of America 1981 Feb;78(2):795-9
-
Convertible Forms of Soluble Uterine Cyclic Nucleotide Phosphodiesterase
Biochim. Biophys. Acta 1981 Jan;66112-20
-
Postsynaptic Inhibition of Neuromuscular Transmission by Trifluoperazine
J. Pharmacol. Exp. Ther. 1981 Jan;21744-50
-
Muscarinic antagonism of the effects of phosphodiesterase inhibitor (methylisobutylxanthine) in embryonic chick ventricle.
The Journal of pharmacology and experimental therapeutics 1980 Nov;215(2):348-56
-
Antagonism of calmodulin by local anesthetics, mepacrine, and propranolol.
Annals of the New York Academy of Sciences 1980 Jan;356441-2
-
Cyclic AMP and Pattern Formation
Nature 1974 Oct;251:572
Books
-
Cells Special Issue on "Phosphodiesterases (PDEs): Therapeutic Targets in Human Health and Disease." see: https://www.mdpi.com/journal/cells/special_issues/8U7R3MRCUH 2024 Jul;
-
Cyclic Nucleotide Phosphodiesterases (PDEs) in Immune Regulation and Inflammation
Electronic Book for Frontiers in Pharmacology 2022 Jun;
-
Cyclic nucleotide phosphodiesterases (PDEs) in immune regulation and inflammation
Book Chapters
-
Bone and the cAMP Signaling Pathway: Emerging Therapeutics
Bone - Metabolic Functions and Modulators: Topics in Bone Biology Series Vol 7 Chapter 16 2012 Jan;271-287
-
Cyclic Nucleotide Phosphodiesterase in Normal and Leukemic Human Lymphocytes and Lymphoblasts
Advances in Cyclic Nucleotide and Protein Phosphorylation Research Vol 16 1984 Jun;16:303-324
Other
-
Methods of Treating Inflammation
United States Patent Publication Number US20090105281 2009 Jan;1-45
-
Synthesis of Antisense Oligodeoxynucleotide of Phosphodiesterase and Inducement of Apoptosis in Human Lymphoblastoid Cells
United States Patent Publication Number US005885834 1999 Mar;
Reviews
-
The Role of PDE8 in T Cell Recruitment and Function in Inflammation.
Frontiers in Cell and Developmental Biology 2021 Apr;9636778
-
Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.
The Biochemical journal 2006 Jan;393(Pt 1):21-41
Title or Abstract | Type | Sponsor/Event | Date/Year | Location |
---|---|---|---|---|
PDEs in Vascular and Metabolic Processes | Panel Discussion | Gordon Research Conference on Cyclic Nucleotide Phosphodiesterases | 2022 | Gordon Research Conference, Les Diablerets Switzerland |
Cyclic Nucleotide Phosphodiesterase 8 as a Target to Treat Autoimmune Inflammation | Talk | Gordon Reseach Conference on Cyclic Nucleotide Phosphodiesterases | 2022 | Gordon Research Conference, Les Diablerets Switzerland |
"Phosphodiesterase 8A domains at the site of leucocyte-endothelial cell adhesion in ulcerative colitis submucosa." | Poster | 13th Congress of ECCO. Inflammatory Bowel Disease | 2019 | 13th Congress of ECCO, Inflammatory Bowel Disease |
Novel Approaches to Overcoming Glucocorticoid Resistance in the Treatment of Lymphoid Leukemias | Poster | Gordon Research Conference | 2018 | Sunday River Maine |
Targeting Phosphodiesterase-8: PDE8 Controls Autoimmune Inflammation by Mechanisms Distinct from PDE4 Inhibition | Talk | Gordon Research Conference | 2018 | Sunday River Maine |
Modulating inflammatory properties of brain derived endothelial cells through PDE8 | Poster | MS Society | 2016 | Rocky Hill Connecticut |
Targeting the PDE8A-Raf-1 kinase signaling complex to treat autoimmune inflammation | Poster | MS Society | 2016 | Rocky Hill Connecticut |
Discovering New Medicines with a Novel Drug Target - PDE8 | Talk | CURE | 2014 | UConn Health |
Targeting PDE8 to treat inflammation in vivo | Gordon Research Conference | 2014 | Mt Holyoke MA | |
The Role of PDE8 in EAE | Poster | 2014 | Mt Holyoke MA | |
Inhibition of Breast Cancer Cell Migration by Activation of cAMP Signaling | Talk | Gordon Research Conference | 2014 | Mt Holyoke MA |
Interplay Between Glucocorticoid and cAMP Signaling on Induction of Apoptosis in Leukemia and Multiple Myeloma Cells | Talk | Gordon Research Conference | 2010 | Waterville Valley NH |
Inhibition of Breast Cancer Metastasis by Activation of cAMP Signaling | Talk | Connecticut Breast Health Initiative | 2008 | New Britain CT |
PDE8 as a Potential Target for Inhibition of Lymphocyte Chemotaxis | Talk | Gordon Research Conference | 2006 | U. of New England Biddeford ME |
Interplay Between Glucocorticoid and cAMP Signaling Pathways on Induction of Apoptosis in Leukemic Cells | Talk | Gordon Research Conference | 2004 | Barga Italy |
Exisulind and Its Derivatives Inhibit Jurkat Cell Proliferation by an Apparent Non-cGMP Dependent Mechanism | Poster | Gordon Research Conference | 2002 | Mt Holyoke MA |
PDE as a potential target for inducing apoptosis of breast cancer cells | Talk | Gordon Research Conference | 2000 | Oxford U. England |
Co-Expression of Four Splice Variants of cGMP-Stimulated Phosphodiesterase (PDE2) in Rat Brain | Talk | Gordon Research Conference | 1999 | Waterville Valley ME |
Cloning of the Human PDE1B1 Gene and its Potential as a Therapeutic Target for Treatment of Leukemia | Talk | Gordon Research Conference | 1998 | New London NH |
PDE1 Molecular Biology and Therapeutics | Talk | William Harvey Research Conference | 1997 | Royal College of Physicians, London England |